Utility of leflunomide in the treatment of complex cytomegalovirus syndromes

Transplantation

Volumn 90, Issue 4, 2010, Pages 419-426

  Avery, Robin K ^a   Mossad, Sherif B ^a   Poggio, Emilio ^a   Lard, Michelle ^a   Budev, Marie ^a   Bolwell, Brian ^a   James Waldman, W ^b   Braun, William ^a   Mawhorter, Steven D ^a   Fatica, Richard ^a   Krishnamurthi, Venkatesh ^a   Young, James B ^a   Shrestha, Rabin ^a   Stephany, Brian ^a   Lurain, Nell ^c   Yen Lieberman, Belinda ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antiviral therapy; CMV; ganciclovir resistance; leflunomide

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TERIFLUNOMIDE; VALGANCICLOVIR;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DNA VIRUS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER FUNCTION TEST; MALE; NEUROPATHY; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LUNG TRANSPLANTATION; OFF-LABEL USE; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VIRAL LOAD;

EID: 77955980893     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e94106     Document Type: Article

References (36)

1. Snydman DR. Persistent clinical impact of cytomegalovirus in organ transplantation. Clin Infect Dis 2008; 47: 883.
2. Rubin RH. The pathogenesis and clinical management of cytomegalo-virus infection in the organ transplant recipient: The end of the 'silo hypothesis.' Curr Opin Infect Dis 2007; 20: 399.
3. Dummer S. Controlling the troll: Management of cytomegalovirus infection after transplantation. Ann Intern Med 2005; 143: 913.
4. Isada CM, Yen-LiebermanB, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cyto-megalovirus infection. Transpl Infect Dis 2002; 4: 189.
5. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.
6. Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760.
7. Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovi-rus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999; 42: 412.
8. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68: 814.
9. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immu-nosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6: 69.
10. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomeg-alovirus infection. Bone Marrow Transplant 2004; 34: 1071.
11. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73: 358.
12. Hertz MI, Jordan C, Savik SK, et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998; 17: 913.
13. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
14. Zeevi A, MorelP, Spichty K, et al. Clinical significanceof CMV-specific T helper responses in lung transplant recipients. Hum Immunol 1998; 59: 768.
15. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20.
16. Singh N, Yu VL. Severing the Gordian knot of prevention of cytomeg-alovirus in liver transplant recipients: The principle is the sword. Liver Transpl 2005; 11: 891.
17. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003.
18. Tomonari A, Iseki T, Takahashi S, et al. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: Comparison between cord blood and bone marrow transplantation. Ann Hematol 2004; 83: 573.
19. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273.
20. Boeckh M, Bowden RA, Gooley T, et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cy-tomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781.
21. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063.
22. Limaye AP. Antiviral resistance in cytomegalovirus: An emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17: 265.
23. Avery RK. Update in management of ganciclovir-resistant cytomega-lovirus infection. Curr Opin Infect Dis 2008; 21: 433.
24. Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovi-rus pneumonia with ganciclovir and intravenous cytomegalovirus im-munoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783.
25. Emanuel D. Treatment of cytomegalovirus disease. Semin Hematol 1990; 27(2 suppl 1):22; discussion 28.
26. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobuline-mia in lung transplant recipients. Transplantation 2001; 71: 242.
27. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl JMed 1995; 333: 1038.
28. Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 1997; 104: 1827; discussion 1836.
29. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001; 3(suppl 2): 20.
30. Lurain NS, Thompson KD, Holmes EW, et al. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66: 7146.
31. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002; 34: 1337.
32. Cline JJ, Garrett AD. Combination antiviral therapy for cytomega-lovirus disease in patients with AIDS. Ann Pharmacother 1997; 31: 1080.
33. Drew WL, Miner RC, Marousek GI, et al. Maribavir sensitivity of cyto-megalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37: 124.
34. John GT, Manivannan J, Chandy S, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005; 37: 4303.
35. John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 2004; 77: 1460.
36. Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8: 38.